ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/087/SRR22444187/SRR22444187_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/086/SRR22444186/SRR22444186_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/085/SRR22444185/SRR22444185_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/088/SRR22444188/SRR22444188_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/087/SRR22444187/SRR22444187_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/085/SRR22444185/SRR22444185_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/086/SRR22444186/SRR22444186_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/088/SRR22444188/SRR22444188_1.fastq.gzprimaryOK200GenomicsSun Yat-Sen Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA906516Homo sapiensThe key modifiers of sensitivity to Arsenic Trioxide (ATO) remained unclear, and we presented a genome-wide scale loss-of-function screening to identify the modulators of cell response to ATO. Overall design: Genome-wide CRISPR-Cas9 screening for HAP1 cells with different treatments (vehicle, and ATO).xref:PubMed:37251921ENAfalseThe genomic landscape of sensitivity to Arsenic Trioxide characterized by Genome-wide CRISPR-Cas9 screeningThe genomic landscape of sensitivity to Arsenic Trioxide characterized by Genome-wide CRISPR-Cas9 screening2025-09-242023-04-27PRJNA906516GSE218982960637251921